REP 2055

Replicor Inc. · Phase 1 active Small molecule

At a glance

Generic name	REP 2055
Also known as	REP 9AC
Sponsor	Replicor Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients (PHASE1, PHASE2)
Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

REP 2055 CI brief — competitive landscape report
REP 2055 updates RSS · CI watch RSS
Replicor Inc. portfolio CI